Nintedanib in NSCLC: clinical trials

Nintedanib in NSCLC: clinical trials

Nintedanib* has been investigated in lung cancer as part of the LUME-Lung clinical trial program. In this section, you will find an overview of the main trials within this program, as well as links to pages for further information.

Nintedanib clinical trials in NSCLC

The approval of nintedanib for the treatment of adult patients with advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy is based on the pivotal Phase III LUME-Lung 1 trial.1

The following table shows the clinical trials of nintedanib in NSCLC; you can find links to further information on this site and published papers.

Ongoing clinical trials in NSCLC

Nintedanib ongoing clinical trials in NSCLC

ADRs, adverse drug reactions; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; SAEs, serious adverse events.



Reck M, et al. Lancet Oncol 2014;15(2):143-55.

2 NCT02668393. (Accessed: June 2020).

3 NCT03017885. (Accessed: June 2020).

4 (Accessed: June 2020).


Reck M, et al. Poster presented at ESMO 2017 (Poster 1382TiP).

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.


© 2020 Boehringer Ingelheim International GmbH. All rights reserved.


Page last updated: August 2020